George Matcham
Follow
Get notifications in MyBN when activity occurs.
George Matcham
Non-Executive Director / Chimeric Therapeutics
Dr George Matcham is a cell therapy expert with over 30 years of experience at Celgene Corporation, where he championed the introduction of cellular immunotherapy and led the establishment of cell therapy & biologics technical development.
Dr Matcham joined Celgene in 1988 when the company was a 30-person startup, and after 3 decades of successful leadership he retired in 2018 with the company shortly being acquired for $74B by Bristol-Myers Squibb (BMS). Dr Matcham was vital to the growth of cell therapy at Celgene. He held several leadership positions including as chief operations officer of Celgene Cellular Therapeutics and senior vice president of CAR T CMC Development where he oversaw clinical supply.
Dr Matcham holds a PhD in Biochemistry from Cardiff University.
Dr Matcham joined Celgene in 1988 when the company was a 30-person startup, and after 3 decades of successful leadership he retired in 2018 with the company shortly being acquired for $74B by Bristol-Myers Squibb (BMS). Dr Matcham was vital to the growth of cell therapy at Celgene. He held several leadership positions including as chief operations officer of Celgene Cellular Therapeutics and senior vice president of CAR T CMC Development where he oversaw clinical supply.
Dr Matcham holds a PhD in Biochemistry from Cardiff University.
Lists and Charts
Total Shareholder Return as at 29/02/24
| Rank | Company | 1 yr | 5 yr |
|---|---|---|---|
| 1062nd | Macarthur Minerals | -23% | |
| 1264th | Sparc Technologies | -37% | 210% |
| 1332nd | Iron Road | -41% | -6% |
| 1644th | Chimeric Therapeutics | -62% |
1790 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
Powered by Morningstar ®
Roles
Year started and most recent title
Share Transactions
Total value as at the date of the transaction
Powered by Morningstar ®
Revenue
| Rank | Company | Revenue | |
|---|---|---|---|
| 864th |  | Chimeric Therapeutics | $4.9m |
| 1010th | | Incannex Healthcare | $1.0m |
| 1011th | | Iron Road | $1,000k |
| 1013th | | Sparc Technologies | $950k |
| 1015th | | Macarthur Minerals | $899k |
1330 listed non wa companies ranked by revenue.
Powered by Morningstar ®
Powered by Morningstar ®
Collapse All Lists and Charts
Person Activity
| NEW ROLE: Non-Executive Director, Chimeric Therapeutics | 12 Apr 2022 |
